Coax, COX and cola

Medical Journal of Australia

Volumn 179, Issue 8, 2003, Pages 397-398

  Dowden, John S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTHRITIS; BACKACHE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; GOVERNMENT; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; MUSCULOSKELETAL DISEASE; PATIENT CARE; PEPTIC ULCER; PHARMACEUTICAL CARE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PUBLICATION; SPORT INJURY; SPRAIN; ULCER;

EID: 0142260968     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05613.x     Document Type: Editorial

References (15)

1. Analysis section. Pharmaceutical Benefits Branch. PBS expenditure and prescriptions January 2000 to December 2000. Available at: www.health.gov.au/pbs/pubs/pbbexp/pbdec00/ (accessed Sep 2003).
2. Pharmaceutical Benefits Pricing Authority. Annual Report for the Year Ended 30 June 2001. Canberra: AGPS, 2001.
3. Kerr SJ, Mant A, Horn FE, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-407.
4. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
6. Cutts C, LaCase A, Tett S. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. Br J Clin Pharmacol 2002; 54: 522-527.
7. Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
8. Budenholzer BR. Rofecoxib did not provide unequivocal benefit over traditional NSAIDs [letter]. BMJ 2002; 325: 161.
9. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in clinical trial of celecoxib [letter]. JAMA 2001; 286: 2398.
10. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959.
11. Wooldridge M. Relief for half a million arthritis sufferers [media release]. Canberra: Commonwealth Department of Health and Aged Care; 1 June 2000. Available at www.health.gov.au/mediarel/yr2000/mw/mw20048.htm (accessed Sep 2003).
12. Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract 2003; 53: 120-125.
13. National Institute for Health Care Management Research and Educational Foundation. Prescription Drugs and Mass Media Advertising 2000. Washington: NIHCM Foundation, 2001.
14. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust 2002; 177: 291-293.
15. Health Research Group. New research results on safety of newly approved drugs causes Health Research Group to extend five-year waiting rule to seven years. Worst Pills Best Pills 2002; 8: 41-43.